MedTrace Logo

Sepsis-3 Study in Northeast Thailand

NCT03379402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1002

Last updated 2026-01-13

No results posted yet for this study

Summary

This is an observational study to evaluate the utility of the latest recommendation to define severity of infection for sepsis patients (sepsis-3), and to identify the aetiology and factors associated with outcome of community-acquired sepsis in Northeast Thailand.

Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.

Conditions

  • Sepsis
  • Community-Acquired Infections

Interventions

OTHER

Specimens collection

On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site. Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.

Sponsors & Collaborators

  • Sanpasitthiprasong Hospital

    collaborator OTHER_GOV

  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER

  • University of Oxford

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2023-03-24
Completion
2023-03-24

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379402 on ClinicalTrials.gov